Alligator Bioscience AB reports financial results for Q2 2025 and provides a business update

On July 10, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported financial results for Q2 2025 and provides a business update (Press release, Alligator Bioscience, JUL 10, 2025, View Source [SID1234654321]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With key regulatory and manufacturing milestones achieved for mitazalimab and strengthened financials, we remain focused on identifying a strategic partner and initiating Phase 3. During the quarter, we successfully completed GMP manufacturing and received clear regulatory feedback from both the FDA and EMA—confirming dose, trial design and paediatric waiver—further strengthening the program’s foundation. In parallel, new biomarker data presented at ASCO (Free ASCO Whitepaper) reinforced mitazalimab’s clinical potential and relevance for patient stratification. Combined with the proceeds from TO 12, these developments move us into the next exciting stage of mitazalimab’s journey."
Søren Bregenholt, CEO of Alligator Bioscience
BUSINESS UPDATE
Mitazalimab

Completion of GMP manufacturing for mitazalimab to support Phase 3 trial readiness in collaboration with development partner.
Paediatric study waiver granted by the European Medicines Agency, streamlining regulatory path ahead of future MAA submission.
Presentation of biomarker data from the Phase 2 trial OPTIMIZE-1 at ASCO (Free ASCO Whitepaper) 2025, showing mitazalimab-induced immune modulation and identifying biomarkers linked to improved outcomes in metastatic pancreatic cancer.
Confirmation from FDA of 900 ug/kg dose and positive scientific advice from EMA further strengthen mitazalimab’s regulatory foundation ahead of Phase 3.
Company

Annual General Meeting held on 7 May 2025; adoption of updated dividend policy aligned with sharpened strategic focus and potential proceeds from asset monetization.
Execution of 1:1000 reverse share split in April 2025, followed by recalculation of terms for TO 12 and TO 13 warrants.
Successful completion of warrant programme TO 12 in May 2025, with 71% of options exercised and SEK 61 million raised before issue costs and partial repayment of loan.
Adjustment of total number of shares to 34,803,898 following TO 12 warrant exercise and share split.
Initiation of Phase 2 clinical trial with HLX22 in HER2-positive breast cancer by Shanghai Henlius; EU Orphan Drug Designation granted for HLX22 in gastric cancer.
FINANCIAL SUMMARY FOR Q2 2025
The financial summaries for the quarterly periods ending 30 June 2025 and 30 June 2024 are presented below.

All amounts in MSEK,
unless specified April – June
2025 April – June
2024
Net sales - 7.6
Operating profit/loss -22.3 -47.4
Profit/loss for the period -1.7 -49.2
Cash flow for the period 5.1 37.4
Cash and cash equivalents 33.9 77.5
Earnings per share before and after dilution, SEK -0.08 -66.36
FINANCIAL SUMMARY FOR H1 2025
The financial summaries for the half-year periods ending 30 June 2025 and 30 June 2024 are presented below.

All amounts in MSEK,
unless specified January – June
2025 January – June
2024
Net sales - 14.6
Operating profit/loss -66.0 -107.0
Profit/loss for the period -10.0 -112.0
Cash flow for the period -29.6 11.3
Cash and cash equivalents 33.9 77.5
Earnings per share before and after dilution, SEK -0.69 -158.50
The full report is attached as a PDF, and is also available on the company’s website: View Source

Alligator will host a webinar on Thursday, July 10 2025, at 3 p.m. CEST/ 9 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the April – June 2025 interim report, which will be followed by a Q&A session.

CoRegen, Inc. Closes More Than $93 Million Financing

On July 09, 2025 CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, reported the close of a $93,390,000 million financing. The proceeds from this round will be used to advance CoRegen’s chemistry, manufacturing, and controls (CMC) development, initiate a Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) program in patients with various solid-tumor types in the first half of 2026 and expand its leadership team with key hires to drive execution and support the company’s growth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing was accomplished under a private placement with a select number of investors. This funding builds upon CoRegen’s prior $28 million raise in early 2024, which supported the acquisition of an exclusive license from Baylor College of Medicine to sponsor the development of its innovative gene regulatory platform.

"We are delighted to have the support of our investors during this pivotal time of growth for the company," said Suneet Varma, CoRegen’s newly appointed Chairman. "This year marks a watershed moment as we build upon the tremendous scientific progress made by Dr. Bert O’Malley and his team at the Baylor College of Medicine. As we prepare to enter the clinic, we are motivated by the belief we have a potentially paradigm-shifting solution in our master gene regulatory platform for patients with some of the most difficult-to-treat solid-tumor cancers, including but not limited to triple negative breast cancer and glioblastoma, for which research to date hasn’t yet moved the needle in a meaningful way in many years. We believe our technology, a type of adoptive cell therapy (ACT), may provide a novel approach for unleashing the healing power of the immune system to eradicate additional forms of cancer."

CoRegen’s platform is based on the groundbreaking work on SRCs (steroid receptor coactivators) in the lab of Bert O’Malley, M.D., Chancellor at the Baylor College of Medicine, who is considered the "Father of Molecular Endocrinology." SRC-3 is overexpressed in most human cancers, and Treg cells’ cancer protection activity is dependent on SRC-3 in this critical immune cell type. Building on this work, CoRegen has carefully engineered cells where SRC-3 is knocked out through application of its proprietary platform, therefore allowing for the targeting of a broad network of immune checkpoint genes for a superior anti-tumor effect. These SRC genes, discovered 30 years ago by Dr. O’Malley, can regulate a wide number of genes in the body, making them an ideal master on-off switch for either stimulating or suppressing gene expression.

(Press release, CoRegen, JUL 9, 2025, View Source [SID1234663767])

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials

On July 9, 2025 LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, reported that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE’s ongoing clinical trials with its proprietary compound LB100 for Ovarian and Colorectal cancers (View Source) (Press release, Lixte Biotechnology, JUL 9, 2025, View Source [SID1234654349]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of Ovarian Clear Cell Carcinoma (OCCC) patients treated with immune checkpoint blockade therapy (clinicaltrials.gov identifier: NCT03026062). The ;study showed that patients having tumors with inactivating mutations in PPP2R1A – the major scaffold subunit of protein phosphatase 2A (PP2A) – had significantly better overall survival, compared with patients who did not have this mutation in their tumors.

Inactivating mutations in PPP2R1A are known to reduce the enzymatic activity of PP2A, which is the target of LIXTE’s lead compound LB-100. Tumors with mutations in PPP2R1A were found to have increased the interferon gamma response pathway, which is known to be associated with improved immune checkpoint responses.

LIXTE is currently investigating the activity of LB-100 in combination with checkpoint immunotherapy in two clinical trials. The first is enrolling patients with OCCC, led by Dr. Jazaeri at MD Anderson Cancer Center, and also is open at Northwester University. In this trial, LIXTE is collaborating with GSK to test LB-100 in combination with dostarlimab (anti PD1). In the second trial, at the Netherlands Cancer Institute, LIXTE is collaborating with Roche to test LB-100 in combination with atezolizumab (anti PDL1) in colon cancer patients.

"Not only did we identify a new biomarker for improved survival with immunotherapy in ovarian cancer, but we also confirmed the correlation of this biomarker with survival benefit in other cancer types," said Dr. Jazaeri, who was co-senior author of the Nature article. "Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A pathway using drugs, which we currently are evaluating in a clinical trial at MD Anderson."

Bas van der Baan, LIXTE’s Chief Scientific Officer, added, "This work extends a body of pre-clinical evidence indicating that LB-100 is strongly synergistic with checkpoint immunotherapy in a range of cancer types. We look forward to the first results of our clinical studies in the second half of this year."

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Metastatic Breast Cancer Study

On July 9, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS, the Company’s personalized off the shelf immunotherapy (Press release, BriaCell Therapeutics, JUL 9, 2025, View Source [SID1234654346]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BriaCell’s first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung metastasis following four doses of BriaCell’s Bria-OTS monotherapy. The complete response was first observed at two months ( previously reported ) and confirmed at four ( previously reported ) and now six months. The patient has been dosed with 12 cycles of Bria-OTS to date.

"These results represent an exciting clinical milestone in the Bria-OTS program," stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, CA, and Principal Investigator for the Bria-OTS study. "We are seeing strong single agent activity in a very challenging population and are eager to explore this approach across more patient subtypes and tumors."

"We are highly encouraged by this remarkable and durable clinical response, especially at the lowest dose level," added Dr. William V. Williams, BriaCell’s President and CEO. "This data underscores the therapeutic potential of our Bria-OTS platform, and we look forward to further evaluating it in combination with a checkpoint inhibitor to improve outcomes in patients with advanced breast cancer."

About Bria-OTS

Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell’s lead candidate Bria-IMT currently being evaluated in a Phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673 ) in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and check point inhibition combination dose expansion cohorts. The Company recently progressed into the dose expansion phase.

FULL-YEAR FINANCIAL REPORT 2024

On July 9, 2025 Valerio Therapeutics reported its full year results (Press release, Valerio Therapeutics, JUL 9, 2025, View Source [SID1234654342]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!